mx computational software-dev fragment-screening
Astex Pharmaceuticals (was Astex Therapeutics at time of XVTF)
Info
Senior crystallographer at Astex Pharmaceuticals (formerly Astex Therapeutics), Cambridge UK / Pleasanton USA. Contributor to the BUSTER-TNT maximum-likelihood refinement package (with Gerard Bricogne at Global Phasing Ltd). A central figure in applying high-throughput X-ray crystallography to fragment-based drug discovery at Astex, a pioneer of the method.
Key Relationships
- Gerard Bricogne / Global Phasing Ltd — BUSTER-TNT collaborators
- Fragment-based drug discovery community intersects with XChem at Diamond Light Source and Frank von Delft (Structural Genomics Consortium)
- X-Ray Validation Task Force member (Read et al., Structure 2011)
Sources
- Read et al. 2011 X-Ray Validation Task Force paper: https://www.cell.com/structure/fulltext/S0969-2126(11)00285-1
- BUSTER-TNT paper: https://pubmed.ncbi.nlm.nih.gov/15572774/